Accession Number ADA582949
Title Exploration of a Novel Persistent Reversal of Pathological Pain: Mechanisms and Mediators.
Publication Date Feb 2013
Media Count 14p
Personal Author A. Ellis L. Loram L. Watkins
Abstract Adenosine 2A receptor agonists when administered intrathecally produces long duration reversal of pain/allodynia in multiple animal models of neuropathic pain. To date we have tested central neuropathy( spinal nerve avulsion), spinal nerve ligation (L5/6 nerve ligation) and a model of sciatic inflammatory neuropathy (SIN). In all of these models the A2AR agonists produces long duration (>4 wk) of pain reversal from a single bolus injection. In addition, we have explored whether the time after injury that the drug is delivered affects the efficacy of the drug. To date, regardless of whether the drug is given in acute neuropathic pain (2 wk) or in well-established neuropathic pain (6 wk after injury), the drug is as effective in both extent of pain reversal and duration. We have begun to explore whether delivery of the drug at the site of injury (perisciatic) is able to reverse the allodynia and the preliminary data looks promising. Lastly, we have begun preliminary studies to identify whether blocking IL-10 at various times after A2AR agonist delivery reverses the efficacy of the drug on pain reversal.
Keywords Adenosine
Adenosines
Antiinflammatory agents
Drugs
Injection
Interleukin 10
Long duration
Pain
Sin(Sciatic inflammatory neuropathy)


 
Source Agency Non Paid ADAS
NTIS Subject Category 57E - Clinical Medicine
57Q - Pharmacology & Pharmacological Chemistry
Corporate Author Colorado Univ. at Boulder.
Document Type Technical report
Title Note Annual rept. 15 Jan 2012-14 Jan 2013.
NTIS Issue Number 1401
Contract Number W81XWH-11-2-0070

Science and Technology Highlights

See a sampling of the latest scientific, technical and engineering information from NTIS in the NTIS Technical Reports Newsletter

Acrobat Reader Mobile    Acrobat Reader